The global rollout of generic Ozempic feels like a tantalizing mirage for Americans. While countries like India and Canada are already enjoying access to more affordable versions of this blockbuster drug, the U.S. is stuck in a patent-induced desert, likely until 2031 or beyond. This disparity isn’t just about timing—it’s a stark reminder of how the U.S. pharmaceutical system prioritizes corporate profits over patient access.
What makes this particularly fascinating is the sheer ingenuity (or cunning, depending on your perspective) of the patent system’s loopholes. Novo Nordisk, the maker of Ozempic, has masterfully exploited these loopholes to extend its monopoly. The standard 20-year patent? Extended. Secondary patents on formulations, doses, and delivery devices? Check. This practice, known as ‘evergreening,’ is a legal sleight of hand that keeps generics at bay.
Personally, I think this is where the system fails patients. The Hatch-Waxman Act, designed to incentivize innovation, has been weaponized to delay competition. What many people don’t realize is that these extensions aren’t just about protecting innovation—they’re about maximizing profits. The result? Americans pay exorbitant prices for a drug that could be far cheaper.
Take the cost of Ozempic in the U.S.: nearly $1,000 a month. Even with Novo Nordisk’s recent price cut to $675, it’s still out of reach for many. Meanwhile, compounded semaglutide products have emerged as a cheaper alternative, but they’re not FDA-approved, raising safety concerns. This gray market is a symptom of a broken system—one that forces patients to choose between affordability and reliability.
If you take a step back and think about it, this isn’t just about Ozempic. It’s about a broader trend in the pharmaceutical industry: the relentless pursuit of profit at the expense of public health. The U.S. patent system, with its receptiveness to evergreening, is complicit in this. While drugmakers argue that patents fund future research, the reality is that they often stifle competition and keep prices artificially high.
A detail that I find especially interesting is the global contrast. In India, Canada, and soon China, Brazil, and South Africa, generic semaglutide is already shaking up the market. By 2026, these countries will likely see a significant drop in prices. The U.S., however, remains an outlier—a testament to the power of patent law in shaping healthcare disparities.
This raises a deeper question: Is the U.S. system truly balanced, as the pharmaceutical industry claims? From my perspective, the answer is a resounding no. While America’s intellectual property system may foster innovation, it does so at the cost of accessibility. Patients in other countries aren’t just getting cheaper drugs—they’re getting them sooner, without the legal gymnastics that define the U.S. market.
What this really suggests is that the U.S. needs a fundamental rethink of its patent laws. Evergreening isn’t just a legal strategy—it’s a moral issue. Until we address this, Americans will continue to pay the price, both literally and figuratively.
In the end, the story of generic Ozempic isn’t just about a drug. It’s about the choices we make as a society. Do we prioritize corporate profits or patient access? The answer, unfortunately, seems clear—and it’s a choice that will haunt us for years to come.
